Shay Shemesh is an experienced finance professional currently serving as the Chief Financial Officer at Yeda - Technology Transfer of Weizmann Institute of Science since February 2021. Previously, Shay held the role of Vice President Finance at Nucleix Ltd. from October 2018 to January 2021 and was the Director of Finance at MultiPhy from September 2010 to November 2018. Prior experience includes serving as CFO at Bioview Ltd. from November 2006 to November 2010 and as a Senior Auditor at PwC from December 2002 to November 2006, where a broad experience with hi-tech companies, multinational corporations, and venture capital firms was developed. Shay holds an MBA from Tel Aviv University (2004-2005) and is a Certified Public Accountant from The Hebrew University of Jerusalem (1999-2003).
This person is not in any teams
This person is not in any offices
YEDA - Technology Transfer Company of Weizmann Institute of Science
Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world. WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute. Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education. Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta. Yeda performs the following activities: ◣ Identifies and assesses research projects with commercial potential. ◣ Protects the intellectual property of WIS and its scientists. ◣ Licenses WIS' inventions and technologies to industry. ◣ Establishes new Startup companies based in WIS Intellectual Property ◣ Channels funding from industry to research projects. Our portfolio covers a broad spectrum of the natural sciences, including: ◣ Agriculture and Plant Genetics, including Bio-fuels ◣ Chemistry and Nanotechnology ◣ Environmental Sciences and Solar Energy ◣ Mathematics and Computer Science ◣ Medical Devices ◣ Pharmaceuticals and Diagnostics ◣ Physics and Electro-Optics ◣ Research Tools